Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease
Yoichi Sato, Jiahe Qiu, Takuo Hirose, Takahiro Miura, Yasunori Sato, Masahiro Kohzuki, Osamu Ito
Abstract
This study indicates that metformin, an indirect AMPK activator slows liver cyst formation and fibrosis in PLD rat model. Metformin attenuates excessive cell proliferation in the liver with the inactivation of mTOR and ERK pathways. Metformin also reduces the expression of proteins responsible for cystic fluid secretion and liver fibrosis. Metformin and AMPK activators may be potent drugs for polycystic liver disease.
Topics & Concepts
MetforminAMPKMedicineMAPK/ERK pathwayEndocrinologyActivator (genetics)Internal medicineFibrosisPI3K/AKT/mTOR pathwayDiabetes mellitusChemistryApoptosisProtein kinase ASignal transductionReceptorKinaseBiochemistryPancreatic function and diabetesMetabolism, Diabetes, and CancerGlycogen Storage Diseases and Myoclonus